Early identification of false positives in high-throughput screening for activators of p53-DNA interaction.

Abstract excerpt

Naturally occurring mutant forms of p53 are deficient for specific DNA binding. However, their specific DNA binding can be reactivated. The search for small molecules that reactivate latent p53 is considered to be a cornerstone in cancer therapy. The authors describe a new homogeneous fluorescent assay approach for the characterization of binding affinities of human wild-type latent and activated p53 using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Algorithms
• Share to Drug Screening Assays, Antitumor